Multiple Sclerosis (MS) is a complex and challenging chronic autoimmune disorder that affects the central nervous system, leading to a wide range of debilitating symptoms.
The field of regenerative medicine has reached a monumental milestone with the U.S. Food and Drug Administration (FDA) approval of RYONCIL®, the first mesenchymal stromal cell (MSC) therapy.
